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Busulfan (Bu) is used as a myeloablative agent in conditioning regimens before allogeneic hematopoietic cell
transplantation (allo-HCT). In line with strategies explored in adults, patient outcomes may be optimized by
replacing cyclophosphamide (Cy) with or without melphalan (Mel) with ﬂudarabine (Flu). We compared
outcomes in 2 consecutive cohorts of HCT recipients with a nonmalignant HCT indication, a myeloid ma-
lignancy, or a lymphoid malignancy with a contraindication for total body irradiation (TBI). Between 2009
and 2012, 64 children received Flu þ Bu at a target dose of 80-95 mg$h/L, and between 2005 and 2008,
50 children received Bu targeted to 74-80 mg$h/L þ Cy. In the latter group, Mel was added for patients with
myeloid malignancy (n ¼ 12). Possible confounding effects of calendar time were studied in 69 patients
receiving a myeloablative dose of TBI between 2005 and 2012. Estimated 2-year survival and event-free
survival were 82% and 78%, respectively, in the FluBu arm and 78% and 72%, respectively, in the BuCy
(Mel) arm (P ¼ not signiﬁcant). Compared with the BuCy (Mel) arm, less toxicity was noted in the FluBu arm,
with lower rates of acute (noninfectious) lung injury (16% versus 36%; P ¼ .007), veno-occlusive disease (3%
versus 28%; P ¼ .003), chronic graft-versus-host disease (9% versus 26%; P ¼ .047), adenovirus infection
(3% versus 32%; P ¼ .001), and human herpesvirus 6 infection reactivation (21% versus 44%; P ¼ .005).
Furthermore, the median duration of neutropenia was shorter in the FluBu arm (11 days versus 22 days;
P < .001), and the patients in this arm required fewer transfusions. Our data indicate that Flu (160 mg/m2)
with targeted myeloablative Bu (90 mg$h/L) is less toxic than and equally effective as BuCy (Mel) in patients
with similar indications for allo-HCT.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic hematopoietic cell transplantation (allo-HCT)
is a potentially curative treatment for a variety of diseases;
however, its use is limited by the risk of graft failure, relapse
of malignant disease, transplantation-related complications/
mortality, and late effects. Busulfan (Bu) is the backbone of
most chemotherapy-based conditioning regimens, and pre-
vious studies have shown awide variability among children’s
responses to Bu-based conditioning before allo-HCT [1-5].
In a previous study, our group demonstrated that a ﬁrst step
in optimizing a conditioning regimen is to target i.v. Bu to an
optimal exposure of 78 mg$h/L (5 mg$h/L) in combination
with cyclophosphamide (Cy) [6].dgments on page 351.
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13.11.027Even with individualization of the Bu dose, the toxicity
(early and late) of the conditioning regimen remains a major
concern. In line with strategies explored in adult transplan-
tation, the next step in further optimizing the pediatric con-
ditioning regimen may be to replace the alkylating agent Cy
with the nucleoside analog ﬂudarabine (Flu) as an immuno-
suppressive agent in the conditioning regimen. Because both
Bu and Cy use glutathione S-transferase (GST) in drug meta-
bolism, a combination of these drugs results in GST depletion,
thereby increasing the risk of toxicity, whereas Flu does not
cause GST depletion [7,8]. In addition, the FluBu combination
may act synergistically on apoptosis of target cells [9].
Most clinical studies in adult patients using this combi-
nation have shown promising results. Compared with BuCy,
FluBu has been associated with reduced toxicity (ie, lower
rates of veno-occlusive disease [VOD] and graft-versus-host
disease [GVHD]) and with improved outcomes [10-13]. A
recent study by Lee et al. [14] did not show a favorable effect
of FluBu, however. That study did not use dose targeting of
Bu, which might have led to low and variable Bu exposures,Transplantation.
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with the FluBu regimen [14]. Data on the use of FluBu in
children are limited [15-18]. Apart from a phase 1 study
reported by Lee et al. [16], pediatric studies have studied
low-dose FluBu in the setting of nonmyeloablative or
reduced-intensity conditioning regimens. Little data have
been published on the use of high-dose, myeloablative FluBu
[19-21], and conditioning regimens have not yet been
compared. Horn et al. [20] studied high-dose FluBu, but
closed the study prematurely owing to a high incidence of
graft failure. Switching from antithymocyte globulin (ATG) to
alemtuzumab has been shown to increase the rate of
engraftment [19].
In this prospective clinical study, we aimed to reduce the
toxicity of the conditioning regimen in pediatric allo-HCT for
nonmalignant indications, myeloid malignancy, or lymphoid
malignancy with a contraindication for total body irradia-
tion, while maintaining myeloablation and efﬁcacy. We
compared the outcomes of 64 pediatric patients included in a
prospective study receiving a FluBu conditioning regimen
between 2009 and 2012 with a recent historical cohort of
50 pediatric patients receiving BuCy (þmelphalan [Mel] in
myeloid malignancies) between 2005 and 2008 in nonma-
lignant and (mainly) myeloid malignant indications for HCT.
The FluBu regimen compared favorably with the BuCy-based
regimen, demonstrating similar efﬁcacy with less toxicity.
PATIENTS AND METHODS
Study Design
This prospective study was performed in the pediatric HCT unit of the
University Medical Center Utrecht and was approved by the institutional
Ethical Committee. Written informed consent was obtained from all
participating patients or their legal representatives before allo-HCT. HCT
data were collected prospectively in the TRIASUS database [22], and were
captured from the database on June 17, 2013, for this analysis.
Patients were prospectively recruited to 2 consecutive conditioning
regimens over an 8-year period. Possible calendar time effects were evalu-
ated using a separate dataset of pediatric patients who received TBI as
myeloablative conditioning in our program between 2005 and 2011,
assuming a similar therapeutic environment in the calendar time periods for
the patients receiving BuCy(Mel) or FluBu and those receiving TBI.
Conditioning Regimens and Patient Inclusion
Patients with a nonmalignant indication (eg, hemoglobinopathies, pri-
mary immune deﬁciencies, metabolic diseases), myeloid malignancy, or
lymphoid malignancy with a contraindication for TBI received a Bu-based
myeloablative conditioning regimen. TBI was contraindicated in patients
with previous craniospinal radiation, poor cardiac function (eg, ejection
fraction<30%), or compromised lung function (eg, forced expiratory volume
in 1 second <80%). Patients with acute lymphoblastic leukemia (ALL)
generally received a TBI-based conditioning regimen.
BuCy(Mel)
Between 2005 and 2009, BuCy(Mel) was the standard conditioning
regimen in our center (based on either national or international protocols)
for all nonmalignant indications, myeloid malignancies, and lymphoid
malignancies with a contraindication for TBI. The initial dose of Bu (Busilvex;
Pierre Fabre Medicament, Boulogne, France) was 120 mg/m2 in patients age
>1 year and 80 mg/m2 in those age <1 year. Bu was administered in a
3-hour infusion once daily, with dose targeting based on therapeutic drug
monitoring to a total area under the curve (AUCday0-4) of 74-82 mg$h/L
(4400-4900 mM$min/day), as described previously [6,17,18,23-25]. In short,
the AUCwas based on 3 to 6 blood samples obtained between 5minutes and
7 hours after the end of Bu infusion on day 1, using a single-compartment
model with linear pharmacokinetics established by Cremers and co-
workers [26-28]. Empirical Bayesian pharmacokinetic parameter estimates
(ie, clearance and volume of distribution) were estimated using the
MwPharm pharmacokinetic software package [29]. The Bu dose was
adjusted only when the AUC differed by >10% from the target AUC. Evalu-
ation of the AUC after dose adjustment was performed on the next day and
at day þ4. All values were used to calculate the total Bu exposure.
Cy was dosed either 60 mg/kg for 2 days in patients with malignant
disease or 50 mg/kg for 4 days in those with nonmalignant disease. Cy wasadministered at least 24 hours after Bu. Mel was added in patients with
myeloid malignancy (ie, myelodysplastic syndrome [MDS] or acute myelog-
enous leukemia [AML]) and in thosewith infant ALL.Melphalanwas dosed at
140 mg/m2 once daily after 2 days of Cy therapy. Serotherapy with ATG
(Thymoglobulin; Sanoﬁ, Cambridge,MA, USA) 10mg/kgwas administered to
all recipients of an unrelated donor graft over 4 days (day 5 to day 2).
FluBu
Patients were included between 2009 and 2012. Flu (Fludara; Sanoﬁ)
40 mg/m2 was given 1 hour before a once-daily 3-hour infusion of Bu.
Starting in 2010, the Bu dose was adjusted to a body weightedependent
dosing regimen described by Bartelink et al. [30]. Bu dose targeting was
based on therapeutic drug monitoring to an AUCday0-4 of 80-95 mg$h/L
(w5400 mM$min/day). Based on reports in adult transplantation, a higher
target exposure of Bu was chosen when used in combination with Flu
[10,31-33]. Serotherapy with ATG 10 mg/kg was administered to unrelated
donor graft recipients from day 5 to day 2 and to cord blood recipients
from day 8 to day 5. It was anticipated that the earlier administration of
ATG in the cord blood recipients would shorten the period of profound T cell
depletion, owing to less in vivo T cell depletion.
TBI
Patients received a cumulative TBI dose of 12 Gy (6  2 Gy). These pa-
tients were included as the TBI cohort only between 2005 and 2011, because
after 2011, the Dutch national conditioning regimen for patients with ALL
was changed to a TBI-free regimen containing clofarabine (CloFluBu). These
patients were not included in the FluBu cohort. The patients who received
TBI were included solely to study possible calendar time effects and had a
similar therapeutic environment as the patients receiving BuCy(Mel) or
FluBu in the time periods studied.
Supportive Care
GVHD prophylaxis, consisting of cyclosporine A (trough level, 200-
250 mg/L) in all patients, remained the same throughout the study period. In
recipients of an unrelated bonemarrow transplant, methotrexatewas added
on days þ1, þ3, and þ6 after HCT, and in unrelated cord blood recipients,
prednisolonewas added up to dayþ28 after HCT. Patients included between
2007 and 2009 who received BuCy(Mel) (n ¼ 6) also received deﬁbrotide as
VOD prophylaxis as part of a trial [34]. VOD was treated with deﬁbrotide
25 mg/kg/day, given in 4 divided doses.
Antimicrobial prophylaxis was standard for all patients. Ciproﬂoxacin
was given starting at the initiation of conditioning and continuing until
neutropenia resolved. Pneumocystis carinii pneumonia prophylaxis was
started once neutropenia was resolved with co-trimoxazole 30 mg/kg
(maximum dose, 960 mg) 3 times per week until a CD4þ cell count >200/mL
was achieved. Patients whowere herpes simplex virus seropositive received
500 mg/m2 (val)acyclovir until day þ28 or until a CD4þ cell count >200/mL
was achieved. Standard antifungal prophylaxis consisted of ﬂuconazole
administered from the start of conditioning up to the resolution of neu-
tropenia (neutrophils >500/L for 3 days). From 2008 onward, patients at
high risk for fungal infections were given voriconazole as prophylaxis [35].
Empirical antifungal therapy with voriconazole (trough level targeted to
2-5 mg/L) was initiated in patients with unexplained fever with negative
bacterial cultures during neutropenia persisting for longer than 72 hours. In
the event of evidence suggesting fungal infection other thanwith Aspergillus,
or invasive yeast infection, liposomal amphotericin-B (AmBisome)was given.
Primary and Secondary Endpoints and Deﬁnitions
Primary study endpoints were overall survival (OS), event-free survival
(EFS; relapse-free survival in malignant diseases), relapse, and nonrelapse
mortality (NRM). OS was deﬁned as the time from transplantation to death;
EFS, as survival from transplantation to last contact, autologous reconsti-
tution (deﬁned as documented <10% donor-derived engraftment), or graft
failure (deﬁned as a lack of neutrophil recovery or transient engraftment of
donor cells after transplantation and/or a requirement for a second trans-
plantation), with relapse and death considered events. NRM was deﬁned as
the time from transplantation to death unrelated to underlying disease. All
surviving patients were censored at date of last contact.
Secondary endpoints were acute GVHD (aGVHD), diagnosed and graded
according to the scheme of Glucksberg et al. [36]; chronic GVHD (cGVHD);
VOD, according to Bearman et al. [37]; acute noninfectious lung injury (ie,
idiopathic pneumonia syndrome [IPS]); and viral reactivation. IPS was
deﬁned as the presence of acute bilateral pulmonary inﬁltrates with cough,
dyspnea, and hypoxemia in the absence of infection. Viral reactivation was
deﬁned as a viral load >1000 cp/mL: adenovirus, human herpesvirus 6
[HHV6], cytomegalovirus [CMV], and Epstein-Barr virus [EBV]. Viral load
was checked weekly up to 4 months after HCT; in the event of low-level
reactivation (>100 cp/mL), levels were checked twice weekly.
Table 1
Clinical Characteristics of the Study Group (n ¼ 151)
Characteristic FluBu BuCy(Mel) P Value*
No. of patients 64 50
Patients receiving BuCy versus BuCyMel, n 38, 12
Age at treatment, yr, median (range) 4.8 (0.16-18.6) 2.6 (0.16-19.4) .076
Follow-up, mo, median (range) 14.9 (2.83-42.1) 58.4 (0.2-95) .001
Bu exposure, mg$h/L, median (range) 91 (74-113) 78 (65-110) <.001
Sex, male/female, n 42, 22 23, 27 .036
TRM risk >20%, <20%, ny 29, 35 26, 24 .478
Transplantation number, 1, 2, 3, n 61, 1, 2 48, 1, 1 .92
Malignant disease, n 27 18 .565
AML (CR1, CR2, CR>2), n 12 (2, 10, 0) 3 (2, 1, 0)
MDS, n 3 6
ALL infant, n 0 2 (1, 0, 1)
ALL (CR1, CR2, CR>2), n 9 (8, 0, 1) 3 (1, 2, 0)
Other, n 3 4
Nonmalignant disease, n 37 32
Bone marrow failure syndrome, n 1 0
Primary immunedeﬁciency, n 19 15
Metabolic disorder, n 16 16
Autoimmune disease, n 1 1
CMV status of recipient þ, , n 36, 28 22, 28 .194
EBV status of recipient þ, , n 45, 19 33, 17 .623
Donor, MSD, UCB, UBM, n 11, 47, 6 10, 28, 12 .076
HLA matched/mismatched, nz 36/28 25/25 .507
CD34þ cells infused,  1.105/kg, median (range) 2 (0.5-9.7) 2.2 (0.1-9.5) .261
CR indicates complete response; MSD, matched sibling donor; UCB, umbilical cord blood; UBM, unrelated bone marrow.
* Comparisons between the FluBu and BuCy(Mel) cohorts using the Mann-Whitney U test.
y The risk of TRM was calculated for each patient based on a comorbidity risk score subdividing the cohort into <20% or >20% TRM risk [40,41].
z HLA matching was based on high-resolution typing for class I and class II (10 alleles) for bone marrow or peripheral blood stem cell donors. For cord blood
donors, intermediate resolution criteria were used on 6 loci (low resolution for loci HLA-A, -B, and -DRB1 by high-resolution typing). One or more allele or
antigen mismatches was considered a mismatch.
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the ﬁrst day of achieving a neutrophile count of >0.5*10e9/L for 3 consec-
utive days, and thrombocyte engraftment (at dayþ180), achieving a count of
count 50  109/L for 7 consecutive days. In addition, the duration of
neutropenia, deﬁned as days of a neutrophil count<0.5109/L between the
time of HCT and neutrophil engraftment, was recorded. In addition, the
number of erythrocyte and thrombocyte transfusions was noted. Chimerism
of >95% was considered full donor chimerism. Donor chimerism of >10%
and <95% was considered mixed.
Statistical Analysis
The duration of follow-upwas deﬁned as the time to the last assessment
for surviving patients or death. To analyze risk factors for outcomes, we
considered patient-related factors (eg, age at date of transplantation, sex,
treatment-related mortality [TRM] risk), disease (ie, malignant or nonma-
lignant disease), and donor (ie, source, donor relationship, and HLA
disparity). The association between these factors and primary and second-
ary endpoints were analyzed using Cox proportional hazards regression
models, with a P value <.10 on univariate analysis and <.05 on multivariate
analysis considered to indicate signiﬁcance. For visualization, outcome
probabilities were calculated using the Kaplan-Meier method. Cumulative
incidence estimates were calculated for all secondary outcomes with death
as the competing event. Given that the addition of Mel to the conditioning
regimen may be the primary cause of toxicity, we also assessed the associ-
ation between the 2 conditioning regimens without patients with a myeloid
malignancy (and infant ALL) in both cohorts, because in the BuCy cohort
these patients would have received Mel.
Propensity score adjustment was performed to adjust for possible
cohort selection of receiving the FluBu or BuCy(Mel) regimen. These scores
were obtained using logistic regression in SPSS [38], including the covariates
stem cell source, HLA matching, indication for HCT, and risk of TRM.
Calculated propensity scores were included in multivariate analysis for the
primary and toxicity endpoints to adjust for comparability. Calendar time
effects in primary and secondary outcome parameters were assessed in a
separate analysis by comparing patients who received TBI between 2005
and 2009 and those who did so between 2009 and 2011. Statistical analyses
were performed using SPSS version 20.0 (IBM, Armonk, NY).
RESULTS
Patient Characteristics
Between 2005 and 2012, 64 patients received FluBu, 50
received BuCy(Mel), and 69 received TBI conditioning beforeHCT. Patientage ranged from2months to19years. Thepatients
in the BuCy(Mel) and FluBu cohorts were comparable in terms
of age and indication for HCT (Table 1). The FluBu cohort
includedmoremalepatients anddemonstrateda trend toward
greater use of umbilical cord blood (P¼ .076) as a donor source.
Because the FluBu cohort was treated in the more recent
period, the duration of follow-up was shorter in this cohort.
Furthermore, Bu exposure was higher in the FluBu cohort,
given the higher target exposure in this conditioning regimen.OS and EFS
Two-year estimated OS and EFS were 82% and 78%,
respectively, for the FluBu cohort and 78% and 72%, respec-
tively, for the BuCy(Mel) cohort (P ¼ not signiﬁcant)
(Figure 1A and B). The number of relapses in patients with
malignant diseasewas not signiﬁcantly different between the
2 cohorts (P¼ .361) (Figure 1C). Moreover, NRM in all patients
did not differ between the 2 cohorts (P ¼ .57). Results of the
univariate analysis are presented in the Appendix. Table 2
presents the signiﬁcant multivariate predictors of OS and
EFS, as well of the various toxicity endpoints.
After adjustment for differences in baseline characteristics
between the treatment cohorts, anticipated TRM risk (based
on European Group for Blood and Marrow Transplantation
comorbidity risk score [39,40]) and diagnosis remained sig-
niﬁcant independent predictors of long-term OS and EFS.
After excluding myeloid malignancies and infant ALL (ie, the
diseases with an indication for Mel), the 2-year estimated OS
and EFS were 91% and 89%, respectively, for the FluBu cohort
and 71% and 66%, respectively, for the BuCy cohort (P ¼ .059
and .036, respectively; Appendix, bottom row).Secondary Endpoints
Cumulative incidence curves for the secondary endpoints
are shown in Figure 2. In univariate analysis, the FluBu
Figure 1. Kaplan-Meier estimates for the probabilities of OS (A) and EFS (B) by treatment cohort in 50 patients treated with BuCy(Mel) (- - -) and 64 patients treated
with Bu-Flu (d). (D) The probability of relapse in patients with malignant disease. The numbers in parentheses indicate number of events and cohort size.
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lung toxicity, and cGVHD, as shown in the Appendix. Table 3
lists the signiﬁcant multivariate predictors of the secondary
endpoints. After adjustment for differences in baseline
characteristics, FluBu and nonmalignant disease were asso-
ciated with a lower risk of acute lung toxicity, VOD, and
cGVHD. There was no impact of the conditioning regimen on
the endpoint aGVHD (P ¼ .886).
The FluBu conditioning regimen was the sole predictor of
a lower risk of viral reactivation (HHV6 and adenovirus), as
shown in Figure 3 and Table 2. The incidence of CMV and EBV
reactivation was not signiﬁcantly different between the
2 cohorts (P ¼ .363 and .155, respectively). All patients in the
BuCy(Mel) and FluBu cohorts had full donor chimerism at
day þ60 as well as at the latest follow-up time point. After
excluding myeloid malignancies (AML, MDS, and juvenile
monomyocytic leukemia) and infant ALL (indication for Mel),
the association between the conditioning regimen and the
secondary endpoints remained the same in the 2 cohorts
(Appendix, bottom row), with lower toxicity in the FluBu
cohort.Table 2
Multivariate Predictors of Survival and EFS and Toxicity Endpoints
Endpoint Adjusted Multivariate Predictors HR 95% CI P Value
OS TRM risk >20% versus <20% 5.86 1.9-17.7 .002
Malignancies versus 2.34 1.0-5.3 .043Other Endpoints
The probability of neutrophil engraftment at day 60 was
98% in both cohorts. Probability of thrombocyte engraftment
(platelets >50$109/L) at day þ180 was higher in the FluBu
cohort (93% versus 82%; P ¼ .005). In addition, time to
thrombocyte engraftment and duration of neutropenia were
signiﬁcantly longer in the BuCy(Mel) cohort compared with
the FluBu cohort (Table 3). In addition, the patients treated
with FluBu required signiﬁcantly fewer erythrocyte trans-
fusions (median, 2 versus 5; P ¼ .009) and thrombocyte
transfusions (median, 5 versus 12; P ¼ .001) after HCT.nonmalignancies
EFS TRM risk >20% versus <20% 3.67 1.5-8.8 .004
Malignancies versus
nonmalignancies
2.18 1.0-4.6 .039
VOD BuFlu versus BuCy(Mel) 0.05 0.0-0.4 .005
IPS BuFlu versus BuCy(Mel) 0.35 0.2-0.8 .013
Malignancies versus
nonmalignancies
0.38 0.1-1.0 .054
cGVHD BuFlu versus BuCy(Mel) 0.40 0.1-1.1 .071
Adenovirus BuFlu versus BuCy(Mel) 0.07 0.0-0.3 .000
HHV6 BuFlu versus BuCy(Mel) 0.24 0.1-0.5 .000
Comparisons between the FluBu and BuCy(Mel) cohorts using the
Mann-Whitney U test.Calendar Time Effects in the TBI Cohort
A myeloablative dose of TBI was used for conditioning
in patients with ALL (n¼ 61; 88%), AML (n¼ 3; 4%), and non-
Hodgkin lymphoma (n¼ 5; 8%) undergoing allo-HCT. Patient
characteristics are summarized in Table 4. The TBI cohort
demonstrated no signiﬁcant calendar time effect for the
primary endpoints OS and EFS or for any the secondary
endpoints (Table 4). In addition, there was no overall trend
toward an effect on the incidence of toxicity.DISCUSSION
This study shows a favorable effect of FluBu compared
with BuCy (Mel) on the outcomes of allo-HCT in a variety of
pediatric malignant and nonmalignant diseases. Despite the
greater Bu exposure in the FluBu cohort compared with the
BuCy cohort, the FluBu regimenwas less toxic and associated
with a shorter neutropenic period and fewer blood trans-
fusions, while maintaining equivalent efﬁcacy. These results
are in line with observations in adults, which show a low
toxicity proﬁle in favor of the FluBu cohort with equivalent or
even improved efﬁcacy [10,11,13,33,41]; however, Horwitz
et al. [42] prematurely closed a study of dual cord blood
transplants using FluBu owing to a high number of graft
failures, and Lee et al. [14] reported lower donor chimerism
in patients treated with Flu combined with untargeted Bu
compared with BuCy(Mel)-treated patients (44% versus
97.2%; P < .001).
The low engraftment in these 2 studies could be related to
the lack of serotherapy (ATG or Campath) in recipients of
unrelated donor transplants owing to lower target AUC
(median, 69.3 mg$h/L in the Horwitz et al. study [42]) or an
untargeted, lower, and variable Bu exposure (in the Lee et al.
study [14]). A pediatric study by Horn et al. [20] also found
a high incidence of graft failure, possibly related to the
low target exposure of Bu. Thus, we propose maintaining
therapeutic drug monitoring and targeting to a higher Bu
exposure of 80 to 95 mg$h/L when using FluBu in children.
Figure 2. Kaplan-Meier estimates for the probabilities of VOD (A), aGVHD (B), cGVHD (C), and IPS (D) by treatment cohort in 50 patients treated with BuCy(Mel) (- - -)
and in 64 patients treated with FluBu (d). The numbers in parentheses indicate number of events and cohort size.
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Anderson Cancer Center [32,43].
Although the follow-up period of in our FluBu cohort may
be short to allow optimal assessment of efﬁcacy, the high rate
of donor engraftment is promising across a wide range of
diagnoses, including metabolic disorders, where donor
chimerism can be difﬁcult to achieve. This is the ﬁrst pedi-
atric study to use myeloablative Bu exposure and to compare
outcomes after FluBu with BuCy(Mel) as a conditioning
regimen.
The optimal approach for comparing different condition-
ing regimens is to perform a prospective randomized trial as
comparisons of single-arm, consecutive trials may suffer
from confounding effects of (un)known factors, including
improved supportive care, introduction of new antifungals,
change in the timing of ATG administration, and increased
experience of the nursing and medical staff. The use of
deﬁned clinical endpoints and prospective inclusion dimin-
ished assessor bias as much as possible. In this study, possible
confounding effects of calendar time were assessed byTable 3
Cell Engraftment and Need for Transfusions
Variable BuC
Duration of neutropenia, d, median (range) 22 (
Time to neutrophil engraftment, d, median (range) 21 (
Time to thrombocyte engraftment, d, median (range) 56 (
Erythrocyte transfusions, n, median (range) 5 (
Thrombocyte transfusions, n, median (range) 12 (
Comparisons between the FluBu and BuCy(Mel) cohorts using the Mann-Whitneyexploiting the data from the TBI cohort, a program that
remained unchanged from 2005 to 2011. The relatively small
size of the TBI cohort (n ¼ 68) might have limited the study’s
power to fully address this limitation, however. Because of
the relatively small sample size, it was not possible to fully
assess differences in outcomes among various subgroups
within the malignant and nonmalignant groups. Further-
more, propensity scores were used to adjust for possible
group selection of the use of a FluBu or BuCy(Mel) condi-
tioning regimen. Although this study may have some limi-
tations, these cannot account for the promising results of less
VOD, less chronic GVHD, shorter duration of neutropenia, and
fewer transfusions seen with the use of FluBu as myeloa-
blative conditioning, despite the higher Bu exposure targeted
in this cohort.
The pattern of toxicity (lung, hepatic, and cGVHD) and
more rapid thrombocyte engraftment with FluBu suggests a
reduction in endothelial damage [44]. The low risk of FluBu
toxicity is most likely related to the nonoverlapping organ
toxicity of the 2 drugs, with Flu not dependent on hepaticy(Mel) FluBu P Value
6-95) 11 (5-102) <.001
9-95) 17 (12-54) .118
14-177) 40 (18-166) .005
0-15) 2 (0-35) .009
2-45) 5 (0-58) .001
U test.
Figure 3. Kaplan-Meier estimates for the probabilities of viral reactivations of adenovirus (A) and HHV6 (B) by treatment cohort in 50 patients treated with
BuCy(Mel) (- - -) and 64 patients treated with FluBu (d). The numbers in parentheses indicate number of events and cohort size.
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of glutathione, toxic Cy metabolites and Bu may have a syn-
ergetic toxic effect [7,8]. This effect is more pronounced whenTable 4
Effects of Calendar Time on Primary and Secondary Outcomes in TBI-Treated
Patients
2004-2008 2009-2011 P Value* HR 95% CI
No. of patients 46 23
Age at treatment, yr,
median (range)
8.6 (1.6-18) 9.6 (2.1-18) .883
Follow-up, mo,
median (range)
43 (0.1-105) 10 (0.1-46) <.0001
Sex, male/female, n 26, 16 21, 6 .167
TRM risk >20%,
<20%, ny
17, 25 13, 14 .421
Transplantation
number 1, 2, 3, n
39, 3, 0 25, 1, 1 .388
Malignant disease
(CR1, CR2,
CR>2), n
13, 25, 4 10, 14, 2 .500
AML, n 3 0
ALL, n 36 24
Other, n 3 3
Nonmalignant
diseases,
0
CMV status of
recipient þ, , n
7, 35 1, 26 .251
EBV status of
recipient þ, , n
7, 35 9, 18 .220
Donor, MSD, UCB,
UBM, n
15, 16, 11 8, 8, 11 .290
HLA matched/
mismatched, nz
26/16 18/9 .106
Two-year EFS, n (%) 16 (65) 8 (65) .647 0.82 0.4-1.9
Two year OS, n (%) 15 (67) 8 (65) .941 0.97 0.4-2.3
cGVHD (>1), n (%) 9 (20) 1 (4) .134 0.21 0.0-1.6
aGVHD, n (%) 14 (30) 9 (39) .968 1.02 0.4-2.4
Lung injury, n (%) 3 (7) 0 (0) .530 0.02 0.0-309
VOD, n (%) 6 (13) 2 (9) .350 0.47 0.1-2.3
HHV6, n (%) 14 (30) 5 (22) .163 0.48 0.2-1.3
EBV, n (%) 4 (9) 2 (9) .793 0.80 0.1-4.4
CMV, n (%) 7 (15) 7 (30) .279 1.8 0.6-5.5
Adenovirus, n (%) 6 (13) 4 (17) .879 1.10 0.3-3.9
* Comparison of the FluBu and BuCy(Mel) cohorts using the
Mann-Whitney U test for patient characteristics and Cox regression for the
time-to-event analysis.
y The risk of TRM was calculated for each patient based on a comorbidity
risk score, subdividing the cohort into <20% or >20% TRM risk [40,41].
z HLAmatchingwas based on high-resolution typing for class I and class II
(10 alleles) for bone marrow or peripheral blood stem cell donors. For cord
blood donors, intermediate resolution criteria were used on 6 loci (low
resolution for loci HLA-A, -B, and -DRB1 by high-resolution typing). One or
more allele or antigen mismatches was considered a mismatch.BuCy is combined with Mel [6,45]. Of the 12 patients
who received BuCyMel, 6 who were enrolled between 2007
and 2009 received deﬁbrotide as prophylaxis. Deﬁbrotide
might have decreased the incidence of VOD in these patients,
as described by Corbacioglu et al. [34]. Thus, without
the use of deﬁbrotide, the cumulative incidence of VOD in the
BuCy(Mel) cohort would have been even greater and the
difference between the cohorts larger. The subgroup analysis
(excluding patients with myeloid malignancy from both
cohorts, who would have received Mel in the BuCy condi-
tioning) demonstrated that the lower toxicity proﬁle of
FluBu was not solely related to dropping Mel from the
conditioning.
Changing the conditioning regimen from BuCy(Mel) to
FluBu in patients with similar indications for HCT signiﬁcantly
reduced the risk of HHV6 and adenovirus infection and
shortened the neutropenic period in these pediatric patients,
effects that have not been reported previously to our knowl-
edge. Our group previously reported that HHV6 reactivation is
signiﬁcantly associated with serious transplantation-related
morbidity and mortality [46,47]. Thus, reducing the inci-
dence of HHV6 reactivation is critical to optimizing HCT
outcomes. The earlier administration of ATG (from day 8 to
day 5) in cord blood recipients might have contributed to
the lower incidence of these viral reactivations, possibly
providing less in vivo T cell depletion and subsequently
resulting in better T cell reconstitution.
In contrast to the unchanged incidence of CMV and EBV
infections seen in the present study, some previous studies
reported that Flu-containing conditioning regimens were
associated with higher incidences of opportunistic in-
fections, such as CMV and EBV, after transplantation because
of the immunosuppressive effect of Flu [48,49]. This effect of
low rates of viral reactivation after cord blood trans-
plantation was previously described by Chiesa et al. [50] in a
series of pediatric cord blood recipients without ATG in the
conditioning regimen. Shortening the period of chemo-
therapy administration from 7 to 9 days (days 9 to 2) in
the BuCy(Mel) cohort to 4 days (days 5 to 2) in the FluBu
cohort, the low toxicity proﬁle of FluBu might have resulted
in the shorter neutropenic period and rapid cell engraftment
in the FluBu cohort.
Now that we and others have shown that FluBu is a safe
and a low-toxicity regimen in pediatric and adult patients,
the next step may be a randomized controlled trial to
conﬁrm our results. A randomized trial is underway in amore
I.H. Bartelink et al. / Biol Blood Marrow Transplant 20 (2014) 345e353 351focused disease population of juvenile monomyocytic leu-
kemia in the Children’s Oncology Group (ClinicalTrials.gov:
NCT01824693). Furthermore, future strategies may focus on
the use of FluBu as a conditioning platform for HCT in all
diseases and for providing better disease control in malig-
nant diseases. Dose targeting of Bu is critical to improve
outcomes of HCT [32,51-54]. Lee et al. [14] showed that
combining Flu with untargeted Bu may result in low donor
chimerism. The optimal dosing of and exposure to Bu in
children, deﬁned using the BuCy(Mel) regimen [6,30,55,56],
were increased in this study when Bu was used in combi-
nation with Flu. In this new FluBu regimen, further
ﬁne-tuning of the Bu dose is needed. For instance, in non-
malignant diseases, exposure deescalation can be used to
determine the lowest acceptable exposure not be associated
with graft failure. More recent studies suggest that optimal
dosing of Flu may be essential as well. Long-Boyle et al. [57]
reported a correlation between Flu concentrations and TRM,
whereas a saturation of intracellular uptake of Flu may
reduce efﬁcacy of higher Flu dosing (personal communica-
tion, J. Long-Boyle, August 2013). Comparedwith the Flu dose
of 160 mg/m2 given over 4 days in the present study, some
previous adult studies used higher cumulative Flu doses,
up to 250 mg/m2 administered over 4 or more consecutive
days [12,32,33]. Lee et al. [14] showed that in children, Flu
250 mg/m2 and Bu with an AUCday0-4 of 72.5-80 mg$h/L are
associated with a high incidence of toxicity, suggesting that
increased Flu exposure may be the cause of this toxicity,
given that the Bu exposurewas lower than that in the present
study. A reduction of the Bu target AUC to 72-76 mg$h/L
decreased toxicity, but the incidence of graft failure remained
signiﬁcant [16]. In contrast, we found a low toxicity rate and
excellent engraftment with a regimen of Bu targeted to
80-95 mg$h/L combined with Flu 160 mg/m2. Pre-HCT
intervention to improve disease control (eg, by adding a
third nonalkylating agent, such as gemcitabine or clofar-
abine) may result in synergistic cytotoxicity, as described
previously [58,59]. Clinically, BuFlu þ Clo was proven safe in
51 very-high-risk patients with AML/MDS (mainly adults)
[60]. Other strategies may include adding low-dose TBI, as
explored by Russell and coworkers [61,62]; however, this
might not be a good option in pediatric patients, given the
association between TBI and severe late effects. Furthermore,
post-HCT interventions with either novel agents (eg, siroli-
mus, histone deacetylase inhibitors, tyrosine kinase in-
hibitors) or immune interventions (eg, cellular), on a FluBu
backbone may be considered [63-67]. Further individualiza-
tion of the target exposure of Bu, Flu, or other drugs in the
conditioning regimen and improved disease control by
disease-speciﬁc additions also may contribute to safer and
more effective allo-HCT.
In conclusion, we have shown that Flu 160 mg/m2 com-
bined with i.v. Bu targeted to a myeloablative exposure
(80-95 mg$h/L) has a positive impact on post-HCT safety,
while maintaining efﬁcacy in pediatric malignant and
nonmalignant HCT indications. This favorable toxicity proﬁle
of this FluBu regimen merit its consideration as conditioning
platform for HCT in all indications in future studies. In addition
to a randomized controlled trial to conﬁrm our results, further
studies are warranted to ﬁne-tune such a FluBu platform.
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APPENDIX
Univariate Predictors of Survival and EFS and Toxicity
Endpoints
Flu ﬂudarabine Bu busulfan Cy cyclophosphamide Mel
Melphalan, TRM-riks treatment related mortality risk, MSD
matched sibling donor, MFD matched family donor, UCB
unrelated cord blood, UBM unrelated bone marrow, OS
overal survival, EFS event free survival VOD veno occlusive
disease,CMV Cytomegalovirus, EBV EpsteineBarr virus,
HHV6 Human Herpesvirus 6
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